Journal article

Anti-inflammatory treatment of bipolar depression: promise and disappointment

Michael Berk, Eduard Vieta, Olivia M Dean


University of Melbourne Researchers


Awarded by Australian National Health and Medical Research Council (NHMRC)

Awarded by Sanofi-Aventis

Awarded by NHMRC

Funding Acknowledgements

MB is supported by a Senior Principal Research Fellowship (1059660 and 1156072) from the Australian National Health and Medical Research Council (NHMRC); reports grant or research support from the National Institutes of Health, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, National Health and Medical Research Council, Medical Research Futures Fund, Beyond Blue, Rotary Health, A2 Milk Company, Meat and Livestock Board, Woolworths, Avant, and the Harry Windsor Foundation; reports having been a speaker for Astra Zeneca, Lundbeck, Merck, Pfizer; reports serving as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Lundbeck Merck, Pfizer, and Servier, outside the submitted work. EV has received grants and served as consultant, advisor, or speaker for Abbott, Allergan, Angelini, Dainippon Sumitomo Pharma, Janssen, Lundbeck, Novartis, Otsuka, Richter, Sage, Sanofi-Aventis, and Takeda, all outside the submitted work. OMD is a RD Wright NHMRC Biomedical Career Developmental Fellow (APP1145634), reports grants from the Brain and Behavior Foundation, Simons Autism Foundation, Stanley Medical Research Institute, Deakin University, Lilly, NHMRC, and Australasian Society for Bipolar and Depressive Disorders/Servier, and has received in kind support from BioMedica Nutraceuticals, NutritionCare, and Bioceuticals, all outside the submitted work.